pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
552
stories
5d
STAT+: Sanofi, Regeneron expand partnership after Dupixent success
stat
5d
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
fiercebiotech
6d
AbbVie's eczema drug shows benefit in Phase 2; BioMarin lays off 117
endpoints
6d
Merck’s anti-TL1A antibody secures a win in ph. 2 hidradenitis suppurativa trial
fiercebiotech
6d
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
biospace
6d
Connect’s Dupixent rival reduces COPD attacks by 85%, but misses a secondary goal
fiercebiotech
6d
Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody
fiercebiotech
6d
No ‘Sunday scaries’: Claire Mazumdar on building Bicara—and knowing when to hand over the reins
biospace
7d
Webinar: From Facility to Delivery: Solving the Complex Science of ADC Linker-Payload Synthesis
biospace
7d
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
biospace
7d
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
7d
Summit snags $2B investment from AstraZeneca, clearing financial overhang
biospace
7d
ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’
biopharma dive
7d
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
biopharma dive
7d
Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancer
fiercebiotech
7d
Researchers slow neurodegeneration in mice by barring T cells from the brain
stat
7d
AstraZeneca scales Summit’s PD-1xVEGF strategy with $2B investment to fuel ADC combos
fiercebiotech
8d
‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
fiercebiotech
8d
ai3Bio emerging from stealth to ‘take the gun out of the hands of the immune system’
fiercebiotech
8d
An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus
biopharma dive
8d
Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
biospace
8d
FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease
biospace
8d
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
biospace
8d
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
biopharma dive
8d
AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover
biospace
8d
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
biospace
8d
Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancer
endpoints
8d
Roche drops muscle-sparing obesity antibody after flunked interim analysis
fiercebiotech
8d
Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir
fiercebiotech
8d
Tolerance continues thymus-focused deals with $560M pact for Tanabe's clinical-stage IL-33 drug
fiercebiotech
← prev
page 2 of 19
next →
